Alto NeuroscienceANRO +3.81%12 PB Ratio is 4.04 as of Jun. 30, 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,229 Biotechnology companies, Alto Neuroscience ranks worse than 62.65% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alto Neuroscience PB Ratio Related Terms
Alto Neuroscience PB Ratio Historical Data
* Premium members only.
The historical data trend for Alto Neuroscience's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alto Neuroscience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alto Neuroscience PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alto Neuroscience's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alto Neuroscience's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alto Neuroscience (ANRO) has a PB Ratio of 4.04 as of Jun. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alto Neuroscience and its competitors. According to the industry distribution chart, Alto Neuroscience ranks #770 out of 1229 companies in the Biotechnology industry, placing it in the top 62.7%.
Is Alto Neuroscience's PB Ratio too high?
Alto Neuroscience's current PB Ratio is 4.04. The Biotechnology industry median PB Ratio is 2.86. Alto Neuroscience's value of 4.04 is 41.3% above this industry median. Based on the distribution chart, Alto Neuroscience ranks #770 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's PB Ratio compare to SANA and AVTX?
According to the Biotechnology industry distribution chart, Alto Neuroscience ranks #770 out of 1229 companies for PB Ratio. This places Alto Neuroscience in the lower half of its industry. The industry median PB Ratio is 2.86. Alto Neuroscience's value of 4.04 is 41.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.86, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alto Neuroscience's current PB Ratio of 4.04 is 41.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alto Neuroscience and its competitors. For the Biotechnology industry, the median PB Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alto Neuroscience's current PB Ratio is 4.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current PB Ratio of 4.04. The current PB Ratio is 4.04 and 41.3% above the Biotechnology industry median of 2.86. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current PB Ratio is 4.04 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score
Get the complete analysis for ANRO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANRO has been successfully added to your 
